---
title: Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation
  of PI3K/Akt/GSK3Î² Pathway in Glioblastoma
date: '2023-10-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37784671/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231003180922&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Our in vitro and in vivo xenograft studies suggest that
  TAGLN2 confers treatment resistance to GBM contributing to tumor recurrence. Altogether,
  TAGLN2 may serve as a potential therapeutically vulnerable target in GBM specifically
  through its role in cell survival and ...'
disable_comments: true
---
CONCLUSION: Our in vitro and in vivo xenograft studies suggest that TAGLN2 confers treatment resistance to GBM contributing to tumor recurrence. Altogether, TAGLN2 may serve as a potential therapeutically vulnerable target in GBM specifically through its role in cell survival and ...